Target intelligence / Profile preview

Cyclin-dependent kinase 1–Cyclin D1–Cyclin-dependent kinase 4–Proliferating cell nuclear antigen–E2F transcription factor 1 cell-cycle axis (CDK1–CCND1–CDK4–PCNA–E2F1 axis) (CDK1–CCND1–CDK4–PCNA–E2F1 axis)

Target
CDK1–CCND1–CDK4–PCNA–E2F1 axis
Molecular classification
Enzyme, Transcription factor, Regulatory protein, Other
01

Overview

The CDK1–CCND1–CDK4–PCNA–E2F1 cell-cycle axis is a fundamental regulatory pathway that governs the transition of eukaryotic cells through the division cycle, particularly the G1 to S phase progression. Cyclin D1 (CCND1) acts as a regulatory subunit that activates Cyclin-dependent kinase 4 (CDK4), which in turn phosphorylates the retinoblastoma protein (Rb), leading to the release of E2F transcription factor 1 (E2F1) (Source: PubMed 2463980). E2F1 then initiates the transcription of genes essential for DNA synthesis and S-phase entry. Proliferating cell nuclear antigen (PCNA) serves as a DNA clamp and scaffold, coordinating DNA replication and repair by interacting with various cell cycle regulators (Source: UniProt P12004). Cyclin-dependent kinase 1 (CDK1) is the primary driver of the G2/M transition but also maintains redundant functions that support G1/S progression (Source: PubMed 17446440). Dysregulation of this axis, such as through CCND1 amplification or loss of CDK inhibitors like p16INK4a, is a hallmark of oncogenesis and leads to uncontrolled cell proliferation (Source: NIH/NCI). Therapeutic targeting of this axis is primarily achieved through CDK4/6 inhibitors like palbociclib and ribociclib, which induce G1 phase arrest in susceptible cancer cells (Source: PubChem CID 5330286).

Other names
CDK-RB-E2F axisG1/S transition pathwayCyclin-CDK-E2F signaling networkCell cycle regulatory axis
02

Mechanism of action

Inhibition of cyclin-dependent kinases (CDK1, CDK4) to prevent Rb phosphorylation and E2F1-mediated transcription, leading to G1 or G2/M phase arrest.

03

Biological functions

Cell cycleCell proliferationDNA replicationOther
04

Disease associations

CancerOther
05

Safety considerations

NeutropeniaLeukopeniaAnemiaFatigueGastrointestinal toxicityMyelosuppression
06

Interacting drugs

Palbociclib

5 more in the full profile.

07

Biomarkers

Cyclin D1 (CCND1) overexpressionRB1 mutation or lossCDK4 amplificationKi-67 proliferation indexPCNA expression levels

Beyond the preview

Go deeper on Cyclin-dependent kinase 1–Cyclin D1–Cyclin-dependent kinase 4–Proliferating cell nuclear antigen–E2F transcription factor 1 cell-cycle axis (CDK1–CCND1–CDK4–PCNA–E2F1 axis) (CDK1–CCND1–CDK4–PCNA–E2F1 axis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin-dependent kinase 1–Cyclin D1–Cyclin-dependent kinase 4–Proliferating cell nuclear antigen–E2F transcription factor 1 cell-cycle axis (CDK1–CCND1–CDK4–PCNA–E2F1 axis) (CDK1–CCND1–CDK4–PCNA–E2F1 axis).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call